Phase 2 Trial of a Nicotinic Agonist in Schizophrenia
Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
The study hypothesis is that 3-2,4 dimethoxybenzylidene anabaseine (DMXB-A), an orally
administered nicotinic cholinergic agonist, will improve attention and other
neuropsychological dysfunctions in schizophrenia, leading to improved psychosocial outcome.
Phase:
Phase 2
Details
Lead Sponsor:
University of Colorado, Denver VA Office of Research and Development